Yantai YenePharma Co., Ltd. Report issue

Government Phase 1

Organization Overview

First Clinical Trial
2018
NCT03495206
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Yantai YenePharma Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (2)

borneol (1 trial)

edaravone (radicava) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhage (Phase 1)

Intracranial Hemorrhages (Phase 1)

Stroke (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2